Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Spillane

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
BMJ Open|April 20, 2024
Protocol for the development of a core outcome set and reporting guidelines for locoregional treatment in neoadjuvant systemic breast cancer treatment trials: the PRECEDENT projectShelley Potter, Kerry Avery, Rosina Ahmed, et al.
ANZ Journal of Surgery|July 21, 2025
Robotic Transabdominal Preperitoneal Inguinal Hernia Repair Is Feasible and Efficient: A Prospective Cohort Study of a Day-Only Protocol From a High-Volume Robotic Surgery Centre Evaluating Short-Term OutcomesJoseph Do Woong Choi, Lauren Bradford, Kim Tang, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 27, 2025
Diagnostic Potential of <sup>68</sup>Ga-NeoB PET/CT with Estrogen Receptor- and Progesterone Receptor-Positive Breast Cancer Undergoing Staging or Restaging for Metastatic DiseaseZahra Sabahi, Andrew Nguyen, Keith Wong, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|July 26, 2024
Exploring locoregional treatment reporting in neoadjuvant systemic breast cancer treatment studies: A systematic reviewMichael Jiang, Kerry Avery, Rosina Ahmed, et al.
Histopathology|May 13, 2010
High Notch1 protein expression is an early event in breast cancer development and is associated with the HER-2 molecular subtypeSarah J Zardawi, Ibrahim Zardawi, Catriona M McNeil, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2025
A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanomaAndrea Boutros, Amelia M Taylor, Isabel Li, et al.
The Journal of Investigative Dermatology|November 23, 2021
Multi-Trait Genetic Analysis Identifies Autoimmune Loci Associated with Cutaneous MelanomaUpekha E Liyanage, Stuart MacGregor, D Timothy Bishop, et al.
European Journal of Cancer (Oxford, England : 1990)|June 10, 2026
Standard neoadjuvant immunotherapy in patients with resectable stage III Melanoma - The early Australian experienceFrancis Proulx-Rocray, Rebecca Symons, Yang Wang, et al.
The New England Journal of Medicine|June 3, 2024
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III MelanomaChristian U Blank, Minke W Lucas, Richard A Scolyer, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
BMJ Open|April 20, 2024
Protocol for the development of a core outcome set and reporting guidelines for locoregional treatment in neoadjuvant systemic breast cancer treatment trials: the PRECEDENT projectShelley Potter, Kerry Avery, Rosina Ahmed, et al.
ANZ Journal of Surgery|July 21, 2025
Robotic Transabdominal Preperitoneal Inguinal Hernia Repair Is Feasible and Efficient: A Prospective Cohort Study of a Day-Only Protocol From a High-Volume Robotic Surgery Centre Evaluating Short-Term OutcomesJoseph Do Woong Choi, Lauren Bradford, Kim Tang, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 27, 2025
Diagnostic Potential of <sup>68</sup>Ga-NeoB PET/CT with Estrogen Receptor- and Progesterone Receptor-Positive Breast Cancer Undergoing Staging or Restaging for Metastatic DiseaseZahra Sabahi, Andrew Nguyen, Keith Wong, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|July 26, 2024
Exploring locoregional treatment reporting in neoadjuvant systemic breast cancer treatment studies: A systematic reviewMichael Jiang, Kerry Avery, Rosina Ahmed, et al.
Histopathology|May 13, 2010
High Notch1 protein expression is an early event in breast cancer development and is associated with the HER-2 molecular subtypeSarah J Zardawi, Ibrahim Zardawi, Catriona M McNeil, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2025
A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanomaAndrea Boutros, Amelia M Taylor, Isabel Li, et al.
The Journal of Investigative Dermatology|November 23, 2021
Multi-Trait Genetic Analysis Identifies Autoimmune Loci Associated with Cutaneous MelanomaUpekha E Liyanage, Stuart MacGregor, D Timothy Bishop, et al.
European Journal of Cancer (Oxford, England : 1990)|June 10, 2026
Standard neoadjuvant immunotherapy in patients with resectable stage III Melanoma - The early Australian experienceFrancis Proulx-Rocray, Rebecca Symons, Yang Wang, et al.
The New England Journal of Medicine|June 3, 2024
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III MelanomaChristian U Blank, Minke W Lucas, Richard A Scolyer, et al.
Pageof 7